top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • Mar 16
  • 1 min read

13/03/2026

























Novartis announced FDA approval of secukinumab for pediatric patients with moderate to severe HS (Ref)


Novartis announced that the US FDA had approved Cosentyx® (secukinumab; anti-IL-17A) for the treatment of pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS)


  • The use of Cosentyx in patients aged 12 years and older with moderate to severe HS weighing 30 kg or more was supported by well-controlled adult HS studies, PK modeling from adult HS and psoriasis trials, and pediatric clinical trial data from the other approved indications


  • Dosing analysis indicated that weight-based dosing of Cosentyx in pediatric patients could provide drug exposure similar to that observed in adult HS patients





bottom of page